# Pembrolizumab in Untreated Extensive SCLC

> **NCT02580994** · PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 125 (actual)

## Conditions studied

- Small Cell Lung Cancer (SCLC)

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** cis/carboplatin and etoposide

## Key facts

- **NCT ID:** NCT02580994
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-08
- **Primary completion:** 2020-09-22
- **Final completion:** 2022-06-22
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2023-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02580994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02580994, "Pembrolizumab in Untreated Extensive SCLC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02580994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*